Advanced Cell Technology
Advanced Cell Technology finalizes two financings totaling over $13 million
Published in Health Business Week, October 13th, 2006
The proceeds will enable continued development of the company's proprietary technology platforms, including the recently announced ACTC technique to generate human embryonic stem cell while preserving the donor embryo's potential for continued development. Included in ACTC's priorities for use of proceeds are the three therapeutic programs currently targeted by ACTC for advancement into the human clinical trial phase. These priorities include therapies for treatment of degenerative eye disease, heart and vascular disease, and technology to...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
Source: Health Business Week (2006-10-13)
More Articles from Health Business Week
- Ace BioSciences
Ace, U.S. Naval Medical Research partner to move Campylobacter vaccine through phase II - AerovectRx
AerovectRx announces funding to commercialize inhaled drug delivery technology - Allied Healthcare Products
Allied Healthcare's drop in fourth quarter net income drags down 2006 results - Alvine Pharmaceuticals
Alvine Pharmaceuticals closes a $21 million series A financing - Amicus Therapeutics
Amicus Therapeutics raises $60 million series D financing - Anormed
Anormed shares begin trading on NASDAQ - More from this issue of Health Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
